Using the da Vinci SP Surgical System for liver and stomach surgeries

A Prospective, Single-Center Investigation of the da Vinci SP® Surgical System in Hepatopancreaticobiliary and Foregut Operations for Benign and Malignant Disease.

This study is testing if the da Vinci SP Surgical System can safely and effectively perform liver and stomach surgeries for adults aged 18 to 80.

Quick facts

• Phase: Not applicable
• Study type: Interventional
• Enrollment: 35 (estimated)
• Ages: 18 Years to 80 Years
• Sex: All
• Sponsor: AdventHealth (Academic / other)
• Locations: 1 site (Tampa, Florida)
• Trial ID: NCT06562179 on ClinicalTrials.gov

What this trial studies

This study evaluates the safety and performance of the da Vinci SP Surgical System in performing hepatopancreaticobiliary and foregut operations, including procedures like gallbladder removal and esophageal surgeries. It aims to collect data on the effectiveness of this robotic surgical system for both benign and malignant conditions. The study will involve patients aged 18 to 80 with specific health criteria, ensuring a controlled environment for assessing outcomes.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 to 80 with specific benign or early malignant conditions affecting the liver, pancreas, or stomach.

Not a fit: Patients with a BMI over 26 or those with advanced metastatic disease may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could enhance surgical precision and recovery times for patients undergoing complex abdominal surgeries.

How similar studies have performed: Other studies using robotic surgical systems have shown promising results, indicating potential for success with this approach.

Eligibility criteria

Inclusion Criteria

Cholecystectomy Stage 1 - Inclusion Criteria:

* Patients between the ages of 18 and 80 years of age
* Either male or female
* BMI ≤ 26 kg/m2
* ASA ≤ 3
* Diagnosed with benign disease

Fundoplication Stage 1- Inclusion Criteria:

* Patients diagnosed with GERD and/or hiatal hernia
* Patients between the ages of 18 and 80 years of age
* Either men or women
* BMI ≤ 26 kg/m2
* ASA ≤ 3

Gastrectomy Stage 2- Inclusion Criteria:

* Patients between the ages of 18 and 80 years of age
* Either men or women
* BMI ≤ 26 kg/m2
* ASA ≤ 3
* Diagnosed with benign or relatively early malignant disease of the stomach
* AJCC 8th edition T0 or T1 tumor pathology
* AJCC 8th edition T2, T3, tumor pathology (following neoadjuvant therapy if necessary) at the discretion of the investigator
* Free of metastatic disease

Distal Pancreatectomy Stage 2- Inclusion Criteria:

* Patients between the ages of 18 and 80 years of age
* Either men or women
* BMI ≤ 26 kg/m2
* ASA ≤ 3
* Diagnosed with benign or malignant disease of the pancreas
* No vascular involvement
* Free of metastatic disease

Pancreaticoduodenectomy Stage 3- Inclusion Criteria:

* Patients between the ages of 18 and 80 years of age
* Either men or women
* BMI ≤ 26 kg/m2
* ASA ≤ 3
* Diagnosed with benign or malignant disease of the pancreas
* Diagnosed with benign or malignant distal bile duct disease
* No vasculature involvement (i.e., no T4 disease, pancreatic or Stage 4a or b disease, or distal bile duct Stage 3b or 4 disease)
* Free of metastatic disease

Esophagectomy Stage 3- Inclusion Criteria:

* Patients between the ages of 18 and 80 years of age
* Either men or women
* BMI ≤ 26 kg/m2
* ASA ≤ 3
* Diagnosed with benign or malignant disease of the esophagus
* AJCC 8th edition T0, T1a, T1b, T2 (without other indications for neoadjuvant therapy) tumor pathology
* AJCC 8th edition some T2, T3, or T4a, (following neoadjuvant therapy) at the discretion of the investigator
* Free of metastatic disease

Hepatectomy Stage 4- Inclusion Criteria:

* Patients between the ages of 18 and 80 years of age
* Either men or women
* BMI ≤ 26 kg/m2
* ASA ≤ 3
* Diagnosed with benign or malignant disease of the liver or bile duct
* Free of metastatic disease, not including metastatic disease to the liver (e.g., colorectal liver metastases)

Exclusion Criteria

Cholecystectomy Stage 1- Exclusion Criteria:

* Subject requiring an emergent operation
* Pregnancy or nursing
* BMI \> 26 kg/m2
* Previous abdominal surgery
* Subjects with malignant disease
* Inability to provide informed consent
* Contraindicated for general anesthesia or minimally invasive surgery

Fundoplication Stage 1- Exclusion Criteria:

* Subject requiring an emergent operation
* Pregnancy or nursing
* BMI \> 26 kg/m2
* Previous abdominal surgery
* Inability to provide informed consent
* Contraindicated for general anesthesia or minimally invasive surgery

Gastrectomy Stage 2- Exclusion Criteria:

* Subject requiring an emergency operation
* Pregnancy or nursing
* BMI \> 26 kg/m2
* Previous abdominal surgery
* Inability to provide informed consent
* Contraindicated for general anesthesia or minimally invasive surgery
* AJCC 8th edition T2, T3, T4a, T4b tumor pathology (without neoadjuvant therapy unless contraindicated)
* Clinical or radiological evidence of distant metastatic disease

Distal Pancreatectomy Stage 2- Exclusion Criteria:

* Subject requiring an emergent operation
* Pregnancy or nursing
* BMI \> 26 kg/m2
* Previous abdominal surgery
* Inability to provide informed consent
* Contraindicated for general anesthesia or minimally invasive surgery
* Tumor involvement with surrounding vasculature (e.g., common hepatic artery, superior mesenteric artery, superior mesenteric vein, portal vein)
* Clinical or radiological evidence of metastatic disease

Pancreaticoduodenectomy Stage 3- Exclusion Criteria:

* Subject requiring an emergent operation
* Pregnancy or nursing
* BMI \> 26 kg/m2
* Previous abdominal surgery
* Inability to provide informed consent
* Contraindicated for general anesthesia or minimally invasive surgery
* Tumor involvement with surrounding vasculature (e.g., T4a for pancreatic disease: common hepatic artery, superior mesenteric artery, superior mesenteric vein, portal vein)
* Tumor involvement with surrounding vasculature (e.g., T3b for bile duct disease: common hepatic artery, superior mesenteric artery, superior mesenteric vein, portal vein)
* Clinical or radiological evidence of metastatic disease

Esophagectomy Stage 3- Exclusion Criteria:

* Subject requiring an emergency operation
* Pregnancy or nursing
* BMI \> 26 kg/m2
* Previous abdominal surgery
* Inability to provide informed consent
* Contraindicated for general anesthesia or minimally invasive surgery
* AJCC 8th edition T2 (in some circumstances), T3, and T4a tumor pathology (without neoadjuvant therapy)
* Clinical or radiological evidence of distant metastatic disease

Hepatectomy Stage 4- Exclusion Criteria:

* Subject requiring an emergency operation
* Pregnancy or nursing
* BMI \> 26 kg/m2
* Previous abdominal surgery
* Inability to provide informed consent
* Contraindicated for general anesthesia or minimally invasive surgery
* Perihilar cholangiocarcinoma (i.e., Klatskin tumor)
* Involvement of major vasculature (ex: portal vein, hepatic artery, or inferior vena cava)
* Clinical or radiological evidence of metastatic disease

Where this trial is running

Tampa, Florida

• AdventhHealth — Tampa, Florida, United States (Recruiting)

Study contacts

• Principal investigator: Sharona Ross, MD — AdventHealth
• Study coordinator: Daniel Robledo, MS

Conditions Hepatopancreaticobiliary and Foregut Operations; SP DaVinci; Gallbladder removal; Esophageal procedures; Gastric resections; Pancreas procedures; Liver procedures